Literature DB >> 3539013

In vitro activity of DQ-2556, a new cephalosporin.

T Fujimoto, T Otani, R Nakajima, T Une, Y Osada.   

Abstract

The in vitro antibacterial activity of DQ-2556, a new semisynthetic cephalosporin, was compared with that of ceftazidime and cefotaxime. The activity of DQ-2556 against members of the family Enterobacteriaceae was roughly comparable to that of cefotaxime. Against Pseudomonas aeruginosa, DQ-2556 was slightly less active than ceftazidime. DQ-2556 was more active than the reference cephalosporins against staphylococci. Haemophilus influenzae and Neisseria gonorrhoeae were also highly susceptible to DQ-2556.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3539013      PMCID： PMC176491          DOI： 10.1128/AAC.30.4.611

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

2.  In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  G P Bodey; D H Ho; B LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

3.  In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin.

Authors:  N Matsubara; S Minami; T Muraoka; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

4.  In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.

Authors:  R N Jones; C Thornsberry; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

5.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

7.  In vitro and in vivo activities of DN-9550, a new broad-spectrum cephalosporin.

Authors:  T Une; T Otani; M Sato; T Ikeuchi; Y Osada; H Ogawa; K Sato; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

8.  Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors.

Authors:  P C Taylor; F D Schoenknecht; J C Sherris; E C Linner
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

9.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity.

Authors:  C H O'Callaghan; P Acred; P B Harper; D M Ryan; S M Kirby; S M Harding
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191
  9 in total
  3 in total

1.  Metabolic disposition of DQ-2556, a new cephalosporin, in rats, rabbits, dogs, and monkeys.

Authors:  K Matsubayashi; S Shintani; M Yoshioka; H Tachizawa
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

2.  In vitro and in vivo activities of DQ-2556 and its mode of action.

Authors:  M Tanaka; M Otsuki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

3.  Penetration of cefazolin, ceftriaxone, cefoperazone, and ceftazidime into human gallbladder tissue and bile.

Authors:  S A Berger; Y Levy; A Halevy; A Gorea; R Orda
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.